These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16312519)

  • 1. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime after intravenous, intramuscular and subcutaneous administration to dogs.
    Monfrinotti A; Ambros L; Prados AP; Kreil V; Rebuelto M
    J Vet Pharmacol Ther; 2010 Apr; 33(2):204-7. PubMed ID: 20444047
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime in elderly patients.
    Higbee MD; Swenson E; Gooch WM
    Clin Pharm; 1989 Jan; 8(1):59-62. PubMed ID: 2643501
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical pharmacokinetics of enoxacin in subjects with renal or hepatic impairment.
    Novelli A; Reali EF; Amato M; Dami A; Fallani S; Periti P
    J Chemother; 1989 Jul; 1(4 Suppl):546-8. PubMed ID: 16312526
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrotoxicity of aminoglycosides. Effects on pharmacokinetics and prevention.
    Brogard JM; Comte F; Spach MO
    Contrib Nephrol; 1984; 42():182-95. PubMed ID: 6398194
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Sánchez-Izquierdo JA; Pedraz JL
    Chemotherapy; 2007; 53(3):194-201. PubMed ID: 17356270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective determination of serum ceftazidime concentrations in intensive care units.
    Aubert G; Carricajo A; Coudrot M; Guyomarc'h S; Auboyer C; Zeni F
    Ther Drug Monit; 2010 Aug; 32(4):517-9. PubMed ID: 20571462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.
    Berkhout J; Visser LG; van den Broek PJ; van de Klundert JA; Mattie H
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1862-6. PubMed ID: 12760859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
    Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
    Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies.
    Dailly E; Brun A; Kergueris MF; Victorri-Vignoli C; Milpied N; Jolliet P
    Int J Antimicrob Agents; 2006 Jun; 27(6):553-6. PubMed ID: 16698237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid.
    Wittmann DH; Schassan HH; Kohler F; Seibert W
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():293-7. PubMed ID: 19803001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
    Phillips M; Smith W; Balan G; Ward S
    J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ceftazidime in normal subjects.
    Harding SM; Ayrton J; Thornton JE; Munro AJ; Hogg MI
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():261. PubMed ID: 19802996
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal tolerance of ceftazidime in animals.
    Capel-Edwards K; Pratt DA
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():241-5. PubMed ID: 19802993
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and pharmacokinetics of tobramycin in patients with chronic urinary tract infections and various degrees of renal impairment.
    Westenfelder SR; Welling G; Madsen PO
    Infection; 1974; 2(2):76-9. PubMed ID: 4842961
    [No Abstract]   [Full Text] [Related]  

  • 18. Penetration of ceftazidime into extracellular fluid in patients.
    Hoffstedt B; Walder M
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():289-92. PubMed ID: 19803000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.
    Nakayama H; Echizen H; Tanaka M; Sato M; Orii T
    Ther Drug Monit; 2008 Feb; 30(1):103-7. PubMed ID: 18223471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.